Papillary Serous Carcinoma of the Uterus: Increased Risk of Subsequent or Concurrent Development of Breast Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Papillary Serous Carcinoma of the Uterus: Increased Risk of Subsequent or Concurrent Development of Breast Carcinoma

Published:2001-12 Issue:3 Volume:83 Page:501-503
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Geisler John P.,Sorosky Joel I.,Duong Hai-Lang,Buekers Thomas E.,Geisler Marcia J.,Sood Anil K.,Anderson Barrie,Buller Richard E.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference18 articles.

1. Cancer statistics, 2000;Greenlee;CA Cancer J Clin,2000

2. The incidence of independent tumors among uterine cancer patients;Bailar;Cancer,1963

3. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients;Magriples;J Clin Oncol,1993

4. Tamoxifen Use in Breast Cancer Patients Who Subsequently Develop Corpus Cancer Is Not Associated with a Higher Incidence of Adverse Histologic Features

5. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14;Fisher;J Natl Cancer Inst,1994

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant diagnosis of endometrial and breast cancer - does the sequence matters?;Gynecologic Oncology Reports;2021-11

2. Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?;Journal of Oncology Pharmacy Practice;2021-05-13

3. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma;Gynecologic Oncology;2017-03

4. Germline mutations of the DNA repair pathways in uterine serous carcinoma;Gynecologic Oncology;2016-04

5. Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas: Treatment of Choice Is Combined Chemotherapy and Radiation;Current Clinical Oncology;2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3